• By ICR Secretariat
  • Posted Tuesday, June 21, 2022

Fierce Pharma Asia—Enhertu's standing ovation; Tessa's $126M CAR-T financing; Samsung's manufacturing deal


AstraZeneca and Daiichi Sankyo's Enhertu looked on track to open a new breast cancer category: HER2-low. Singapore's Tessa Therapeutics grabbed $126 million in a series A to advance its CAR-T programs. Samsung Biologics signed a manufacturing contract with Novartis for the first time. And more.